Showing 13 to 24 of 176 results
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Wegovy Use Among Teens Increases by 50% in 2024
Data shows a 50% increase in Wegovy prescriptions for American teens in 2024, reaching 14.8 per 100,000 adolescents, despite concerns about long-term effects and limited insurance coverage; this follows a strong recommendation from the American Academy of Pediatrics in January 2023.
Progress
36% Bias Score
China Combats Childhood Obesity with Fitness Initiatives
China is tackling rising childhood obesity (nearly 19 percent of children aged 6-17 are overweight or obese) with a national weight management campaign, increased school physical education, and the growing popularity of children's fitness events like the Spartan Kids race.
China Combats Childhood Obesity with Fitness Initiatives
China is tackling rising childhood obesity (nearly 19 percent of children aged 6-17 are overweight or obese) with a national weight management campaign, increased school physical education, and the growing popularity of children's fitness events like the Spartan Kids race.
Progress
28% Bias Score
Proposed Australian Sugar Tax: \$1.4 Billion Revenue, Health Debate
A Labor MP proposes a 20% tax on sugary drinks in Australia, aiming to raise \$1.4 billion in revenue and reduce sugar content in beverages, while facing opposition due to concerns about its effect on low-income earners and effectiveness in combating obesity.
Proposed Australian Sugar Tax: \$1.4 Billion Revenue, Health Debate
A Labor MP proposes a 20% tax on sugary drinks in Australia, aiming to raise \$1.4 billion in revenue and reduce sugar content in beverages, while facing opposition due to concerns about its effect on low-income earners and effectiveness in combating obesity.
Progress
36% Bias Score
France Expands Access to Anti-Obesity Drugs
The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.
France Expands Access to Anti-Obesity Drugs
The French government will allow general practitioners to prescribe Wegovy and Mounjaro to combat obesity, affecting nearly 50% of French adults; a plan launching in September will address this through education, healthcare, sports, and medication, aiming to curb cardiovascular deaths.
Progress
40% Bias Score
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Weight Regain After Stopping Weight-Loss Injections: An Oxford Study
A University of Oxford study reveals that individuals using weight-loss injections regain a significant portion of lost weight within 10 months of stopping treatment, regardless of the injection type; newer, more effective drugs lead to greater weight loss but also greater weight regain.
Progress
48% Bias Score
WeightWatchers Partners with GLP-1 Provider Amidst Financial Troubles
WeightWatchers, facing bankruptcy in the US, partners with UK GLP-1 weight-loss medication provider CheqUp, integrating its app to support users of weight-loss injections like Wegovy and Mounjaro, aiming for improved and sustainable weight loss, as demand for traditional programs declines.
WeightWatchers Partners with GLP-1 Provider Amidst Financial Troubles
WeightWatchers, facing bankruptcy in the US, partners with UK GLP-1 weight-loss medication provider CheqUp, integrating its app to support users of weight-loss injections like Wegovy and Mounjaro, aiming for improved and sustainable weight loss, as demand for traditional programs declines.
Progress
48% Bias Score
UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market
In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...
UK Obesity Crisis: Weight-Loss Drug Success Creates Dangerous Black Market
In the UK, the rising popularity of GLP-1 weight-loss medication like Wegovy and Ozempic, despite strict NHS access, has created a black market with reports of misuse leading to hospitalizations; while effective for weight loss and related health problems, unregulated access poses serious health ris...
Progress
44% Bias Score
High Visceral Fat Poses Significant Health Risks for Men
High visceral fat in men, often hidden by muscle or societal acceptance, increases mortality risk; 40-46% of US men are obese, and new medications offer potential solutions, but require further study and a holistic approach.
High Visceral Fat Poses Significant Health Risks for Men
High visceral fat in men, often hidden by muscle or societal acceptance, increases mortality risk; 40-46% of US men are obese, and new medications offer potential solutions, but require further study and a holistic approach.
Progress
72% Bias Score
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Tirzepatide Shows Superior Weight Loss Compared to Semaglutide in Clinical Trial
A new study comparing tirzepatide and semaglutide in 751 obese participants found tirzepatide produced significantly greater weight loss (average 50 pounds, 20.2% body weight) versus semaglutide (average 33 pounds, 13.7%), attributed to its dual hormone action; however, the study's open-label design...
Progress
52% Bias Score
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
Turkey Launches Nationwide Obesity Program Amidst Systemic Concerns
Turkey's Ministry of Health is launching a nationwide obesity program involving public BMI measurements and referrals to health centers, aiming to reach 10 million citizens in two months; however, experts point to underlying issues like poverty, unhealthy food access, and insufficient public policie...
Turkey Launches Nationwide Obesity Program Amidst Systemic Concerns
Turkey's Ministry of Health is launching a nationwide obesity program involving public BMI measurements and referrals to health centers, aiming to reach 10 million citizens in two months; however, experts point to underlying issues like poverty, unhealthy food access, and insufficient public policie...
Progress
44% Bias Score
UK Heart Health Declines Sharply: Deaths and Diagnoses Soar
The UK is experiencing the worst start to a decade for heart health in 50 years, with cardiovascular deaths among working-age adults rising by 18% since 2019 to 21,975 in 2023, alongside record increases in heart failure, atrial fibrillation, and diabetes diagnoses, and lengthening hospital waiting ...
UK Heart Health Declines Sharply: Deaths and Diagnoses Soar
The UK is experiencing the worst start to a decade for heart health in 50 years, with cardiovascular deaths among working-age adults rising by 18% since 2019 to 21,975 in 2023, alongside record increases in heart failure, atrial fibrillation, and diabetes diagnoses, and lengthening hospital waiting ...
Progress
32% Bias Score
Showing 13 to 24 of 176 results